13 research outputs found
Global and Regional Burden of Bacterial Antimicrobial Resistance in Urinary Tract Infections in 2019
Background: There are still no detailed data about the burden of bacterial antimicrobial resistance (AMR) in urinary tract infections (UTI). Concrete knowledge of global and regional bacterial AMR data is crucial for developing informed programs and policies to control bacterial AMR and for prudent use of antibiotics to optimize antibiotic therapy in patients with UTI. This study aimed to provide comprehensive global and regional estimates for the AMR burden of UTI in 2019. Methods: Data were obtained from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), including death, disability-adjusted life-years (DALYs), year lived with disability (YLD), and years of life lost (YLL) for bacterial AMR in UTI for 7 GBD super-regions, 21 regions, 14 pathogens, 13 antibiotic classes, and 66 pathogen-antibiotic combinations in 2019. The estimates were based on two counterfactual scenarios: drug-susceptible infection and no infection. Results: Globally, there were 64.89 thousand deaths (95% uncertainty interval [UI]: 45.86–93.35) attributed to and 0.26 million deaths (95% UI: 0.18–0.36) associated with bacterial AMR in UTI in 2019. Among regions, the all-age death rates were higher in southern Latin America, tropical Latin America, and Europe and lower in sub-Saharan Africa. Escherichia coli and Klebsiella pneumoniae accounted for more than 50% of deaths attributable to and associated with AMR, and resistance was high among multiple types of antibiotic class, including fluoroquinolones, carbapenems, and third-generation cephalosporins. There were 2 pathogen-drug combinations that caused more than 6000 resistance-attributable deaths: third-generation cephalosporin-resistant Escherichia coli and fluoroquinolone-resistant Escherichia coli. Conclusions: AMR in UTI is an unignorable health problem, both for the management of urology disease and for global antibiotic resistance. Special tailored strategies, including enhanced surveillance and rational use of antibiotics, should be developed for different regions according to the region-specific pathogen-antibiotic situations and resources
Glucose-responsive, antioxidative HA-PBA-FA/EN106 hydrogel enhanced diabetic wound healing through modulation of FEM1b-FNIP1 axis and promoting angiogenesis
The diabetic wounds remain to be unsettled clinically, with chronic wounds characterized by drug-resistant bacterial infections, compromised angiogenesis and oxidative damage to the microenvironment. To ameliorate oxidative stress and applying antioxidant treatment in the wound site, we explore the function of folliculin-interacting protein 1 (FNIP1), a mitochondrial gatekeeper protein works to alter mitochondrial morphology, reduce oxidative phosphorylation and protect cells from unwarranted ROS accumulation. And our in vitro experiments showed the effects of FNIP1 in ameliorating oxidative stress and rescued impaired angiogenesis of HUVECs in high glucose environment. To realize the drug delivery and local regulation of FNIP1 in diabetic wound sites, a novel designed glucose-responsive HA-PBA-FA/EN106 hydrogel is introduced for improving diabetic wound healing. Due to the dynamic phenylboronate ester structure with a phenylboronic acid group between hyaluronic acid (HA) and phenylboronic acid (PBA), the hydrogel is able to realize a glucose-responsive release of drugs. Fulvic acid (FA) is added in the hydrogel, which not only severs as crosslinking agent but also provides antibacterial and anti-inflammatory abilities. Moreover, the release of FEM1b-FNIP1 axis inhibitor EN106 ameliorated oxidative stress and stimulated angiogenesis through FEM1b-FNIP1 axis regulation. These in vivo and in vitro results demonstrated that accelerated diabetic wounds repair with the use of the HA-PBA-FA/EN106 hydrogel, which may provide a promising strategy for chronic diabetic wound repair
Direct Analysis of Biofluids by Mass Spectrometry with Microfluidic Voltage-Assisted Liquid Desorption Electrospray Ionization
Signal suppression
by sample matrix in direct electrospray ionization–mass
spectrometric (ESI-MS) analysis hampers its clinical and biomedical
applications. We report herein the development of a microfluidic voltage-assisted
liquid desorption electrospray ionization (VAL-DESI) source to overcome
this limitation. Liquid DESI is achieved for the first time in a microfluidic
format. Direct analysis of urine, serum, and cell lysate samples by
using the proposed microfluidic VAL-DESI-MS/MS method to detect chemical
compounds of biomedical interest, including nucleosides, monoamines,
amino acids, and peptides is demonstrated. Analyzing a set of urine
samples spiked with dihydroxyphenylalanine (DOPA) showed that the
assay had a linear calibration curve with <i>r</i><sup>2</sup> value of 0.997 and a limit of detection of 0.055 ÎĽM DOPA.
The method was applied to simultaneous quantification of nucleosides,
that is, cytidine, adenosine, uridine, thymidine, and guanosine in
cell lysates using 8-bromoadenosine as internal standard. Adenosine
was found most abundant at 26.5 ± 0.57 nmol/10<sup>6</sup> cells,
while thymidine was least at 3.1 ± 0.31 nmol/10<sup>6</sup> cells.
Interestingly, the ratio of adenosine to deoxyadenosine varied significantly
from human red blood cells (1.07 ± 0.06) to cancerous cells,
including lymphoblast TK6 (0.52 ± 0.02), skin melanoma C32 (0.82
± 0.04), and promyelocytic leukemia NB4 cells (0.38 ± 0.06).
These results suggest that the VAL-DESI-MS/MS technique has a good
potential in direct analysis of biofluids. Further, because of the
simplicity in its design and operation, the proposed microfluidic
liquid DESI source can be fabricated as a disposable device for point-of-care
measurements